文献速递白血病淋巴瘤

miR-130b与miR-128a是t(4;11) MLL-AF4急性白血病的谱系特异性协同驱动因子

miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
PubMed 文献 · Blood · 2021-01-01

本研究在Mll-AF4小鼠模型中证实,miR-130b和miR-128a是MLL-AF4下游靶点,可各自驱动白血病前期向急性白血病转化并维持疾病表型。miR-130b过表达导致混合/BCP/髓系白血病,miR-128a过表达导致pro-B ALL,并鉴定NR2F6和SGMS1为新的肿瘤抑制因子。

要点

  • miR-130b和miR-128a是MLL-AF4下游靶点,可独立驱动白血病发生。
  • 两miRNA过表达诱导不同谱系白血病,重现人类疾病特征。
  • NR2F6和SGMS1被验证为MLL-AF4+白血病的新肿瘤抑制因子。

核心结论

  • miR-130b和miR-128a是t(4;11) MLL-AF4急性白血病必需的谱系特异性协同驱动因子。

研究设计与样本

  • 研究采用完全小鼠Mll-AF4体内模型,聚焦原代患者白血病母细胞中上调的miR-130b和miR-128a。

主要发现

  • miR-130b和miR-128a是MLL-AF4下游靶点,可各自驱动白血病前期向急性白血病转化并维持疾病表型。
  • miR-130b过表达导致混合/BCP/髓系白血病,由LMPP群体传播。
  • miR-128a过表达导致pro-B ALL,由高度扩增的Il7r+c-Kit+母细胞群体维持。
  • 两miRNA诱导的分子和表型改变完全重现人类疾病,包括中枢神经系统浸润和MLL-AF4表达特征激活。
  • NR2F6和SGMS1被鉴定为两miRNA下游靶点,并经广泛验证确认为MLL-AF4+白血病的新肿瘤抑制因子。

临床怎么用

  • 为MLL重排白血病提供识别关键协同驱动因子的平台,可用于剖析白血病前期向白血病转化及谱系可塑性并测试新疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

t(4;11) MLL-AF4 acute leukemia is one of the most aggressive malignancies in the infant and pediatric population, yet we have little information on the molecular mechanisms responsible for disease progression. This impairs the development of therapeutic regimens that can address the aggressive phenotype and lineage plasticity of MLL-AF4-driven leukemogenesis. This study highlights novel mechanisms of disease development by focusing on 2 microRNAs (miRNAs) upregulated in leukemic blasts from primary patient samples: miR-130b and miR-128a. We show that miR-130b and miR-128a are downstream targets of MLL-AF4 and can individually drive the transition from a pre-leukemic stage to an acute leukemia in an entirely murine Mll-AF4 in vivo model. They are also required to maintain the disease phenotype. Interestingly, miR-130b overexpression led to a mixed/B-cell precursor (BCP)/myeloid leukemia, propagated by the lymphoid-primed multipotent progenitor (LMPP) population, whereas miR-128a overexpression resulted in a pro-B acute lymphoblastic leukemia (ALL), maintained by a highly expanded Il7r+c-Kit+ blast population. Molecular and phenotypic changes induced by these two miRNAs fully recapitulate the human disease, including central nervous system infiltration and activation of an MLL-AF4 expression signature. Furthermore, we identified 2 downstream targets of these miRNAs, NR2F6 and SGMS1, which in extensive validation studies are confirmed as novel tumor suppressors of MLL-AF4+ leukemia. Our integrative approach thus provides a platform for the identification of essential co-drivers of MLL-rearranged leukemias, in which the preleukemia to leukemia transition and lineage plasticity can be dissected and new therapeutic approaches can be tested.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Malouf C, Antunes ETB, O'Dwyer M, et al. miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia. Blood. 2021. PMID: 34111240. doi:10.1182/blood.2020006610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。